MedCap is a holding company that acquires and develops niche companies in the life science industry in Northern Europe. The group operates through three business areas: Assistive Tech, MedTech, and Specialty Pharma. Its activities include the sale of assistive devices, the sale and contract manufacturing of pharmaceuticals, the sale of medical technology, and the contract manufacturing of food products. MedCap serves as an active long-term owner, providing capital, expertise, and network access to its subsidiaries to support their growth and international expansion. The group manages its operations through independent subsidiaries, exercising governance primarily through the boards of the owned companies.

Summarised from the company's own disclosures, fiscal year ended Dec 2025

Industry Conglomerates Homepage medcap.se/en
Sector Industrials IR page medcap.se/en
Tags
life science, assistive technology, medical technology, specialty pharmaceuticals, contract manufacturing, holding company, niche companies, northern europe, MedCap Assistive Tech Holding AB, MedCap Surgical Holding AB, Unimedic Pharma Holding AB, Cardiolex Medical AB, Inpac Holding AB, Multi-ply Components Ltd, Takura AB, Abilia, Erimed International AB, Rehab Holding ApS, Huka B.V., Trident Industri AB, Biopsafe ApS
Press page medcap.se/investerare-media/press-media/pressmeddelanden

Metrics

Valuation  
Market cap kr 7.785B
Market cap (USD) $ 766.274M
P/E 35.31
PEG 1.52
P/BV 5.34
P/S 9.52
P/OCF 67.34
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE 16.1%
ROI 13.7%
ROIC 14.3%
Profit margin 10.5%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) 23.2%
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity 10.7%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 36
Quality score 41.2%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015
Revenue 2.108B 1.807B 1.587B 1.111B 916.3M 817.4M 386.2M 39.2M 851.668M 816.918M —
Net profit 220.7M 209.2M 172.5M 118M 98.1M 60.9M 53.7M — 73K 19.452M —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015
Share price 534.3 576.5 297.5 167 173.9 — 138 86.4 34.29 — —
Price performance 12m -0.07 0.94 0.78 -0.04 0.17 — 0.6 1.52 0.09 — —

Filed figures

Figure Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (SEK) — 426M 475M 169M 237M 211M 267M
↳ YoY growth +11.5% -64.4% +40.0% -11.1% +26.9%
↳ 5y CAGR -8.9%
Borrowings, non-current (SEK) — 41.5M 18.3M — — — —
Lease liabilities (SEK) — 142M 172M 156M 147M 284M 267M
Cash and deposits (SEK) 20.8M 147M 140M 236M 188M 370M 370M
Intangible assets (SEK) — 217M 208M 199M 309M 305M 566M
Right-of-use assets (SEK) — 138M 168M 150M 142M 275M 253M
Net debt (borrowings + leases - cash) (SEK) — 37.2M 50.2M — — — —
Cash flow detail
Operating cash flow (SEK) — 116M 116M 85.5M 228M 360M 343M
Purchases of property, plant and equipment (SEK) — -11.3M -45.3M -26.3M -22.1M -41.7M -25.7M
Purchases of intangible assets (SEK) — -13.1M -15.6M -18M -17.2M -24.5M -36.5M
Change in receivables (cash effect) (SEK) — 15.6M -36.5M -160M -8.3M 44.1M -47M
Change in inventories (cash effect) (SEK) — -16.5M -16M -10.8M -47.2M 42.3M 22.4M
Change in payables (cash effect) (SEK) — -5.3M -2.9M 24.4M -13.9M -14.7M 29.4M
Share buybacks (cash effect) (SEK) — — 0.00 -7.4M 0.00 -35.9M -26.1M
Interest paid (cash effect) (SEK) — -8.6M -7.7M -3M -8.5M -6.6M -6.4M
Income taxes paid (cash effect) (SEK) — -22.3M -24.2M -23.9M -33.3M -73.6M -91.3M
Operating cash flow before change in receivables (SEK) — 100M 153M 245M 236M 316M 390M
Free cash flow (OCF - PPE - intangibles) (SEK) — 91.2M 55.4M 41.2M 189M 294M 281M
Income detail
Total comprehensive income (SEK) — 45.1M 116M 139M 165M 225M 168M
Comprehensive income to owners (SEK) — 43.9M 114M 138M 165M 223M 167M
Reported — — — — — — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Regulatory Interim report

THIRD QUARTER JULY-SEPTEMBER 

  • The Group’s net sales amounted to SEK 566.7 (501.5) million, an increase of 13 percent.

  • The Group’s EBITA was SEK 154.7 (90.1) million, an increase of 72 percent. EBITA adjusted for items affecting comparability*) amounted to 118.3 (91.1) million, an increase of 30 percent.

  • The EBITA margin was 27.3 (18.0) percent. Adjusted for items affecting comparability*), the margin was 20.9 (18.2) percent.

  • Profit after tax amounted to SEK 84.8 (51.3) million.

  • Basic earnings per share amounted to SEK 5.7 (3.4). Adjusted earnings per share amounted to SEK 2.3 (3.6)*).

  • Cash flow from operating activities was SEK 96.1 (61.9) million.

NINE MONTHS JANUARY-SEPTEMBER

  • The Group’s net sales amounted to SEK 1,729.6 (1,517.0) million, an increase of 14 percent.

  • The Group’s EBITA was SEK 393.8 (266.5) million, an increase of 48 percent. EBITA adjusted for items affecting comparability*) amounted to 352.4 (272.8) million, an increase of 29 percent.

  • The EBITA margin was 22.8 (17.6) percent. Adjusted for items affecting comparability*), the EBITA margin was 20.4 (18.0) percent.

  • Profit after tax amounted to SEK 209.8 (155.7) million.

  • Basic earnings per share amounted to SEK 14.0 (10.4). Adjusted earnings per share amounted to SEK 10.6 (10.6)*).

  • Cash flow from operating activities was SEK 270.1 (191.2) million.

 
The Group delivered a strong third quarter with both organic and acquisition-driven growth and high profitability. All business areas contributed to the earnings growth. Net sales for the quarter increased by 13 percent, which included organic growth of 5 percent. All business areas reported net sales and earnings growth, which contributed to the adjusted EBITA increase of 30 percent.

The Assistive Tech business area performed well, with good net sales growth and strong margins. The improvement in earnings was mainly driven by Abilia and the acquisition of LivAssured. Other companies in the business area delivered a stable overall performance, with good growth in Huka but weaker growth in a couple of the companies.

MedTech reported strong net sales growth during the quarter, driven by the nutrition product area and the acquisition of Biopsafe. Net sales for ECG products declined compared with the strong previous year, while the market position is considered unchanged. The smaller companies in the business area performed well and contributed to the improvement in earnings. Overall, the business area reported a strong margin and solid earnings growth.

Specialty Pharma’s net sales increased as a result of the acquisition of XGX Pharma in July of the previous year and higher non-recurring sales of unlicensed pharmaceuticals.
During the quarter, further progress was made in integrating Unimedic and XGX, with a focus on commercialising and developing existing products and new products in the pipeline. The business area's margin is expected to strengthen as recently launched products as well as existing products introduced into additional markets account for an increasing share of net sales. Business development activities progressed in the right direction during the third quarter.

Acquisitions
Acquisitions are a core part of MedCap’s strategy for creating long-term growth and achieving the Group's financial targets. We continuously develop relationships with companies that could become part of the MedCap Group and actively seek new opportunities across Europe. During the quarter, a couple of acquisition processes were concluded without resulting in acquisitions. However, the number of ongoing discussions remains relatively high and the prospects for further acquisitions are still considered favourable.
During the quarter, the outstanding contingent consideration for XGX was remeasured. The acquisition and the contingent consideration model have developed in line with expectations to date, resulting in a positive one-off effect excluded from adjusted EBITA.
MedCap has a strong balance sheet and low leverage, providing ample capacity for further acquisitions. The ambition is to continue using the Group’s financial strength to create long-term value for shareholders.

In summary
MedCap’s strategy is based on investing in and developing profitable small and medium-sized Life Science companies. A decentralised model combines local entrepreneurship and business responsibility with the advantages of being part of a larger group. The focus is on developing the existing businesses while using investments and acquisitions to broaden the Group’s platforms and create new growth areas. The Group delivered a strong third quarter, with solid net sales growth, high profitability and adjusted EBITA increasing by 30 percent.
 
Anders Dahlberg, CEO
Stockholm, October 23, 2026

Valberedning i MedCap utsedd Bull 0 Bear 0 Routine

Regulatorisk

Vid årsstämman 2026 beslutades att valberedningen i MedCap AB (publ) ska bildas genom att styrelsens ordförande, baserat på ägarstatistik vid tredje kvartalets utgång från Euroclear Sweden AB, kontaktar de tre röstmässigt största aktieägarna, vilka vardera har rätt att utse en ledamot att jämte styrelsens ordförande utgöra valberedning.

Valberedningen inför årsstämman 2027 i MedCap AB (publ) består av följande personer:

Thomas Bergh, utsedd av Linc AB
Jan Dworsky, utsedd av Swedbank Robur Fonder
Claes Murander, utsedd av Lannebo Fonder
Karl Tobieson, styrelseordförande MedCap AB

Valberedningens uppgift är att lämna förslag till årsstämman 2027 avseende val av stämmoordförande, ordförande och övriga ledamöter i styrelsen samt av revisor. Valberedningens uppgift är också att lämna förslag till styrelse-, utskotts- och revisionsarvoden samt principer för utseende av valberedning inför årsstämman 2028.

Aktieägare som vill lämna förslag till valberedningen kan göra detta skriftligen under följande adress:

Valberedningen
MedCap AB
Engelbrektsgatan 9-11
114 32 Stockholm

Förslag kan även lämnas per e-post till följande adress: [email protected]

För att valberedningen ska hinna behandla inkomna förslag bör dessa vara valberedningen tillhanda senast den 1 februari 2027. Valberedningens förslag kommer att presenteras i god tid innan årsstämman och offentliggöras på bolagets hemsida i samband därmed.

Regulatorisk

MedCap AB (publ) har utsett Johan Boqvist till Affärsområdeschef för Medicinteknik, med tillträde i första kvartalet 2027.

Johan kommer närmast från rollen som Strategi- och M&A-chef på Mölnlycke, och har tidigare erfarenhet från Privatläkarna, Unilabs, Capio, Gunnebo och EY.

”Vi välkomnar Johan Boqvist som Affärsområdeschef för Medicinteknik. Johan kombinerar erfarenhet från flera områden inom sjukvård och medicinteknik med affärsutveckling och M&A internationellt, som kommer bidra till att fortsätta utveckla Affärsområdet Medicinteknik”, säger Anders Dahlberg, VD för MedCap.

Stockholm den 1 oktober 2026

MedCap AB (publ)

Anders Dahlberg

VD

Prompts

MedCap (ticker MCAP), listed in Sweden.

ETFs Holding MedCap

ETF Weight in ETF Shares Market value As of
AVDV 0.04% 131,739 $ 7.262M Nov 16, 2026
AVDS 0.04% 2,369 $ 130.583K Nov 16, 2026
DFIS 0.02% 16,481 $ 904.69K Nov 12, 2026
AVSD 0.01% 1,009 $ 55.617K Nov 16, 2026
DXIV 0.01% 358 $ 19.652K Nov 12, 2026
DFSI 0.01% 1,287 $ 70.647K Nov 12, 2026
DFIC 0.00% 13,351 $ 732.875K Nov 12, 2026
DFAX 0.00% 7,148 $ 392.375K Nov 12, 2026
DFAI 0.00% 9,502 $ 521.592K Nov 12, 2026
AVDE 0.00% 16,551 $ 912.314K Nov 16, 2026